Evidence map›Paper›PMID 31220955›Full record

ReviewExpert opinion on drug delivery2019

Extended release formulations using silk proteins for controlled delivery of therapeutics.

Burcin Yavuz, Laura Chambre, David L Kaplan

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Recent progress of polymeric microneedle-assisted long-acting transdermal drug delivery.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Burcin Yavuza Department of Biomedical Engineering , Tufts University , Medford , MA , USA.
Laura Chambrea Department of Biomedical Engineering , Tufts University , Medford , MA , USA.
David L Kaplana Department of Biomedical Engineering , Tufts University , Medford , MA , USA.
Tufts University · US

Funding

Models to Predict Protein Biomaterial PerformanceU01EB014976 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI BUEHLER, MARKUS J., KAPLAN, DAVID L. · 2012 to 2020
$5.2M
Focal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor SitesR01NS094218 · NINDS · TUFTS UNIVERSITY MEDFORD · PI CHIU, BILL, KAPLAN, DAVID L. · 2017 to 2021
$1.7M
NIBIB NIH HHS U01 EB014976NINDS NIH HHS R01 NS094218
6 · The paper itself

Abstract

introductionSilk is a promising biomaterial for controlled delivery of therapeutics and has a unique protein chemistry that can be tuned to form different carrier formats. The protein has been studied for sustained release depot systems for the targeted or localized delivery of drugs. AREAS COVERED: An overview of natural silk proteins for controlled delivery of therapeutics is provided, with a focus on the features of silk proteins that allow them to be useful tools for controlled delivery. Recent applications of natural silk proteins as controlled delivery systems are also summarized. EXPERT OPINION: The versatility of silk proteins makes them desirable biomaterials for a broad range of applications for controlled delivery of both small and large molecules. Further, the degradation profile leading to peptides and amino acids provides compatibility with pH-sensitive therapeutics. While silk sericin and spider silks are under study, silk fibroin extracted from silkworms (e.g.

Indexed as

AnimalsBiocompatible MaterialsBombyxDelayed-Action PreparationsFibroinsHumansHydrogelsSilkBiocompatible MaterialsDelayed-Action PreparationsFibroinsHydrogelsSilkcontrolled releasedrug deliveryhydrogelsimplantsmicroneedlesnanoparticlesSilk

Identifiers

PMID31220955
PMCPMC6642005
OpenAlexW2953283300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.